Telemetry Compatibility. PURCHASER and SPACECOM will jointly examine telemetry to verify that the PURCHASER hardware and software is functioning correctly.
Telemetry Compatibility Sample Clauses
Related to Telemetry Compatibility
Compatibility The Spacecraft Bus shall be compatible with standard GPS interfaces as defined in [**Redacted**].
Year 2000 Compatibility Borrower shall take all action necessary to assure that Borrower's computer based systems are able to operate and effectively process data including dates on and after January 1, 2000. At the request of Bank, Borrower shall provide Bank assurance acceptable to Bank of Borrower's Year 2000 compatibility.
Interfaces 1 2 wire i/f (towards PSTN) -------------------------------------------------------------------------------------------------------- 2 2 wire i/f (towards standard handset) -------------------------------------------------------------------------------------------------------- 2.2 FUNCTIONS -------------------------------------------------------------------------------------------------------- 1 Selective Call -------------------------------------------------------------------------------------------------------- 2 Conference Call (up to four participants) ----------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------- 3 MANAGEMENT COMMUNICATION -------------------------------------------------------------------------------------------------------- 3.1 COMMUNICATION INTERFACES see OPTera Product Description SEC. 5.2.3 - Standard Communications Interfaces and SEC.7.3 - Management Communication -------------------------------------------------------------------------------------------------------- 1 F- Interface (RS 232) -------------------------------------------------------------------------------------------------------- 2 Q- interface as gateway to the EMS -------------------------------------------------------------------------------------------------------- 3 Qecc Routing (2 level IS-IS) -------------------------------------------------------------------------------------------------------- 4 Q I/F (Ethernet) -------------------------------------------------------------------------------------------------------- 5 Optical Supervisory Channel ----------------------------------------------------------------------------------------------------------------------------------- 6 OSC - wavelength IR IR IR see OPTera Product - bitrate Description SEC. 5.2.2 - optical span limit - Per Wavelength - transmission protocol Optical Service Channel and SEC.7.3 - Management Communication ----------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------- 3.2 O & M INTERFACES ----------------------------------------------------------------------------------------------------------------------------------- 1 8 x Remote Control Inputs ----------------------------------------------------------------------------------------------------------------------------------- 2 Remote Control Outputs ----------------------------------------------------------------------------------------------------------------------------------- 3 Card LED support ----------------------------------------------------------------------------------------------------------------------------------- 4 Subrack LED support ----------------------------------------------------------------------------------------------------------------------------------- 5 Rack Alarm support ----------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------
Configuration The configuration for the Purchase Right Aircraft will be the Detail Specification for Model 767-3S2F aircraft at the revision level in effect at the time of the Supplemental Agreement. Such Detail Specification will be revised to include (i) changes required to obtain required regulatory certificates and (ii) other changes as mutually agreed upon by Boeing and Customer.
Metering 1. If the Producer desires to sell electric power to the Company, the Company shall provide, own and maintain at the Producer's expense all necessary meters and associated equipment to be utilized for the measurement of energy and capacity for determining the Company's payment to the Producer pursuant to an applicable agreement.
Infrastructure (a) The Borrower has and will maintain a sufficient infrastructure to conduct its business as presently conducted and as contemplated to be conducted following its execution of this Agreement.
Monitoring System In each case in which the Custodian has exercised delegated authority to place Assets with a Foreign Custodian, the Custodian shall establish a system, to re-assess or re-evaluate selected Foreign Custodians, at least annually in accordance with Rule 17f-5(c)(3).
Feedback Distributor shall provide Company with prompt written notification of any comments or complaints about the Products that are made by Customers, and of any problems with the Products or their use that Distributor becomes aware of. Such written notification shall be the property of Company, and shall be considered to be part of Company’s Confidential Information.
Review Systems The Asset Representations Reviewer will maintain and utilize an electronic case management system to manage the Tests and provide systematic control over each step in the Review process and ensure consistency and repeatability among the Tests.
Clinical Data and Regulatory Compliance The preclinical tests and clinical trials conducted by the Company, and to the knowledge of the Company, the preclinical tests and clinical trials conducted on behalf of or sponsored by the Company, that are described in, or the results of which are referred to in, the Registration Statement, the Time of Sale Prospectus or the Prospectus were and, if still pending, are being conducted in all material respects in accordance with the protocols, procedures and controls designed and approved for such studies and with standard medical and scientific research procedures and all applicable laws and regulations, including, without limitation, 21 C.F.R. Parts 50, 54, 56, 58, and 312; each description of the results of such studies is accurate and complete in all material respects and fairly presents the data derived from such studies, and the Company and its subsidiaries have no knowledge of any other studies the results of which are inconsistent with, or otherwise call into question, the results described or referred to in the Registration Statement, the Time of Sale Prospectuses or the Prospectus; the Company and its subsidiaries have made all such filings and obtained all such Permits as may be required by the Food and Drug Administration of the U.S. Department of Health and Human Services or any committee thereof or from any other U.S. or foreign government or drug or medical device regulatory agency, or health care facility Institutional Review Board (collectively, the “Regulatory Agencies”) for the operation of the Company’s business as currently conducted, except as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; neither the Company nor any of its subsidiaries has received any notice of, or correspondence from, any Regulatory Agency requiring the termination, suspension or modification of any clinical trials that are described or referred to in the Registration Statement, the Time of Sale Prospectus or the Prospectus; and the Company and its subsidiaries have each operated and currently are in compliance in all material respects with all applicable rules and regulations of the Regulatory Agencies except as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.
